Announcements Trials
Browse Landscape

Phase

Phase 2 44Phase 1 18Phase 3 9Phase 1/2 5Phase NA 2Phase 2/3 2Phase 4 1

Status

Withdrawn 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Colorectal Neoplasms 1Ascites 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × aflibercept × Clear all
NCT01646554 2017-05-09

BOS3

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT00327444 2013-01-01

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Sanofi

Phase 2/3 Completed
58 enrolled 11 charts
Gynecologic

Ascites, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡